Form 4: iCAD Director Andy Sassine Reports Share and Option Conversion Following RadNet Merger

Director Andy Sassine's holdings in iCAD, Inc. were converted or terminated as a result of the company's merger with RadNet, Inc. on July 17, 2025.

Summary

• Andy Sassine, a Director of iCAD, Inc., reported changes in his beneficial ownership due to the merger of iCAD, Inc. with Trio Merger Sub, Inc., a wholly-owned subsidiary of RadNet, Inc., effective July 17, 2025.
• His 1,198,382 shares of iCAD Common Stock were disposed of and converted into the right to receive 0.0677 shares of RadNet Common Stock per iCAD share.
• Stock options with an exercise price below $7.20 (Eligible iCAD Options) were assumed by RadNet and converted based on the 0.0677 exchange ratio.
• Stock options with an exercise price of $7.20 or higher terminated without consideration.
• Following these transactions, Andy Sassine beneficially owns 0 shares of iCAD Common Stock and 0 derivative securities of iCAD.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, which provides a clear exit and liquidity for shareholders. While some options terminated without value, the overall event is a planned corporate action, indicating a successful conclusion to the acquisition process for the company and its shareholders.

Positives

• The merger provides a clear exit strategy and liquidity for iCAD shareholders, including the reporting person.
• Eligible stock options were converted into RadNet options, preserving some value for option holders.

Negatives

• Stock options with an exercise price of $7.20 or higher terminated without any consideration, resulting in a loss of potential value for those specific options.
• The reporting person no longer holds direct beneficial ownership in iCAD, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4, as it reports a past transaction.

Industry Context

The merger indicates consolidation within the medical imaging or healthcare technology sector, with RadNet, a leading provider of outpatient diagnostic imaging services, acquiring iCAD, a company focused on AI-powered cancer detection solutions. This suggests a strategic move by RadNet to integrate advanced AI capabilities into its services.

Stakeholder Impact

• Shareholders (iCAD): Received RadNet shares (and cash for fractional shares) in exchange for their iCAD shares, providing liquidity and continued equity exposure in the combined entity.
• Option Holders (iCAD): Eligible option holders had their options converted to RadNet options, while others saw their options terminate without value.
• Employees (iCAD): Implied integration into RadNet, potentially affecting roles and compensation structures, though not explicitly detailed.
• Customers (iCAD): Will now be served by RadNet, potentially benefiting from a broader service offering.

Key Dates

Keywords

SEC Form 4, iCAD Inc, RadNet Inc, Merger, Stock Options, Common Stock, Beneficial Ownership, Corporate Acquisition, Director Holdings, Equity Conversion